Alnylam Pharmaceuticals Aktie
273,70
EUR
-6,20
EUR
-2,22
%
321,18
USD
-6,05
USD
-1,85
%
Werbung
Alnylam Pharmaceuticals Aktie Analyse
| 30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
| 24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
| 26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
| 21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
| 10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
| 14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
|
Werbung
|
|||
Werbung
Werbung